Abstract
Background: Urinary tract infections (UTIs) are the most frequent bacterial infections commonly seen in females. A high degree of antimicrobial resistance in uropathogens has challenged the use of therapeutic agents. Fosfomycin, which is an old antibiotic with distinctive characteristics, seems to be a promising novel therapeutic agent with a good bactericidal activity towards multi-drug resistant (MDR) uropathogens.
Objectives: The main objective of the study is to evaluate the antibacterial activity of fosfomycin among uropathogens causing cystitis.
Methods: The study was carried out between 2017-2018. A total of 2060 UTI suspects from outpatient departments (OPDs) and inpatient departments (IPDs) were screened. Out of 2060 screened patients, 1658 were IPD patients, and 402 were OPD patients. The patient’s midstream urine samples were collected aseptically and processed according to standard protocols. The frequency of extendedspectrum- beta lactamases (ESBLs) producer and carbapenem resistance were estimated, respectively. Cultures with significant growth of uropathogens were identified, and minimum inhibitory concentration (MIC) to fosfomycin was determined by agar dilution (AD) and by E-test methods.
Results: 184 out of 2060 (8.9%) urine samples showed significant growth of uropathogens. Uropathogenic Escherichia coli (UPEC) (64%, 118/184) was found to be the most isolated uropathogen. Among these Gram-negative uropathogens, 80% were ESBLs producers, 43.2% were carbapenemresistant, and 78% isolates were found to be MDR. The fosfomycin susceptibility for UPEC was 95% by the AD method.
Conclusions: This study suggests that fosfomycin is reasonably effective and can be used in the treatment of MDR uropathogens along with uncomplicated UTIs.
Keywords: UTI, fosfomycin, MIC, MDR, E-test method, gram-negative bacilli.
Graphical Abstract
[1]
Foxman B. Urinary tract infection syndromes: Occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 2014; 28(1): 1-13.
[http://dx.doi.org/10.1016/j.idc.2013.09.003] [PMID: 24484571]
[http://dx.doi.org/10.1016/j.idc.2013.09.003] [PMID: 24484571]
[2]
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 2015; 13(5): 269-84.
[http://dx.doi.org/10.1038/nrmicro3432] [PMID: 25853778]
[http://dx.doi.org/10.1038/nrmicro3432] [PMID: 25853778]
[4]
Raz R. Fosfomycin: An old--new antibiotic. Clin Microbiol Infect 2012; 18(1): 4-7.
[http://dx.doi.org/10.1111/j.1469-0691.2011.03636.x] [PMID: 21914036]
[http://dx.doi.org/10.1111/j.1469-0691.2011.03636.x] [PMID: 21914036]
[5]
Minardi D, d’Anzeo G, Cantoro D, Conti A, Muzzonigro G. Urinary tract infections in women: Etiology and treatment options. Int J Gen Med 2011; 4: 333-43.
[http://dx.doi.org/10.2147/IJGM.S11767] [PMID: 21674026]
[http://dx.doi.org/10.2147/IJGM.S11767] [PMID: 21674026]
[6]
Chooramani G, Jain B, Chauhan PS. Prevalence and antimicrobial sensitivity pattern of bacteria causing urinary tract infection; study of a tertiary care hospital in North India. Clin Epidemiol Glob Health 2020; 8(3): 890-3.
[http://dx.doi.org/10.1016/j.cegh.2020.02.018]
[http://dx.doi.org/10.1016/j.cegh.2020.02.018]
[7]
Patel HB, Soni ST, Bhagyalaxmi A, Patel NM. Causative agents of urinary tract infections and their antimicrobial susceptibility patterns at a referral center in Western India: An audit to help clinicians prevent antibiotic misuse. J Family Med Prim Care 2019; 8(1): 154-9.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_203_18] [PMID: 30911498]
[http://dx.doi.org/10.4103/jfmpc.jfmpc_203_18] [PMID: 30911498]
[8]
Kot B. Antibiotic resistance among uropathogenic Escherichia coli. Pol J Microbiol 2019; 68(4): 403-15.
[http://dx.doi.org/10.33073/pjm-2019-048] [PMID: 31880885]
[http://dx.doi.org/10.33073/pjm-2019-048] [PMID: 31880885]
[9]
Gardiner BJ, Stewardson AJ, Abbott IJ, Peleg AY. Nitrofurantoin and fosfomycin for resistant urinary tract infections: Old drugs for emerging problems. Aust Prescr 2019; 42(1): 14-9.
[http://dx.doi.org/10.18773/austprescr.2019.002] [PMID: 30765904]
[http://dx.doi.org/10.18773/austprescr.2019.002] [PMID: 30765904]
[10]
Fajfr M, Balik M, Cermakova E, Bostik P. Effective treatment for uncomplicated urinary tract infections with oral fosfomycin, single center four year retrospective study. Antibiotics (Basel) 2020; 9(8): 1-9.
[http://dx.doi.org/10.3390/antibiotics9080511] [PMID: 32823650]
[http://dx.doi.org/10.3390/antibiotics9080511] [PMID: 32823650]
[11]
Derington CG, Benavides N, Delate T, Fish DN. Multiple-dose oral fosfomycin for treatment of complicated urinary tract infections in the outpatient setting. Open Forum Infect Dis 2020; 7(2): a034.
[http://dx.doi.org/10.1093/ofid/ofaa034] [PMID: 32123690]
[http://dx.doi.org/10.1093/ofid/ofaa034] [PMID: 32123690]
[12]
Gupta K, Bhadelia N. Management of urinary tract infections from multidrug-resistant organisms. Infect Dis Clin North Am 2014; 28(1): 49-59.
[http://dx.doi.org/10.1016/j.idc.2013.10.002] [PMID: 24484574]
[http://dx.doi.org/10.1016/j.idc.2013.10.002] [PMID: 24484574]
[13]
Gupta K, Hooton TM, Naber KG, et al. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52(5): e103-20.
[http://dx.doi.org/10.1093/cid/ciq257] [PMID: 21292654]
[http://dx.doi.org/10.1093/cid/ciq257] [PMID: 21292654]
[14]
Al-Badr A, Al-Shaikh G. Recurrent urinary tract infections management in women: A review. Sultan Qaboos Univ Med J 2013; 13(3): 359-67.
[http://dx.doi.org/10.12816/0003256] [PMID: 23984019]
[http://dx.doi.org/10.12816/0003256] [PMID: 23984019]
[15]
Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007; 29(1): 62-5.
[http://dx.doi.org/10.1016/j.ijantimicag.2006.08.039] [PMID: 17189097]
[http://dx.doi.org/10.1016/j.ijantimicag.2006.08.039] [PMID: 17189097]
[16]
Senol S, Tasbakan M, Pullukcu H, et al. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother 2010; 22(5): 355-7.
[http://dx.doi.org/10.1179/joc.2010.22.5.355] [PMID: 21123160]
[http://dx.doi.org/10.1179/joc.2010.22.5.355] [PMID: 21123160]
[17]
Qiao LD, Zheng B, Chen S, et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: An uncontrolled, open-label, multicentre study. BMJ Open 2013; 3(12)e004157
[http://dx.doi.org/10.1136/bmjopen-2013-004157] [PMID: 24309172]
[http://dx.doi.org/10.1136/bmjopen-2013-004157] [PMID: 24309172]
[18]
Collee JG, Mackie TJ, McCartney JE. Mackie & McCartney practical medical microbiology. Harcourt Health Sciences 1996.
[19]
Bailey WE, Scott EG. Diagnostic microbiology.London, The CV
Mosby Company; Henry Kimpton In: 1962.
[20]
Procop GW, Church DL, Hall GS, Janda WM. Koneman’s Color Atlas and Textbook of Diagnostic. Philadelphia: Wolters Kluwer 2017; pp. 845-53.
[21]
Wayne PA. Clinical and laboratory standards institute.Performance
standards for antimicrobial susceptibility testing 2011;
Available from: https://clsi.org/standards/products/microbiology/documents/m100/
[22]
Performance Standards for Antimicrobial Susceptibility Testing.
Twenty-Fourth Informational Supplement. Wayne, USA: CLSI
2014..
[23]
O’Neill J. Tackling drug-resistant infections globally: Final report and recommendations. Rev Antimicrob Resist 2016; 2016: 4-5.
[24]
Banerjee S, Sengupta M, Sarker TK. Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens. Indian J Urol 2017; 33(2): 149-54.
[http://dx.doi.org/10.4103/iju.IJU_285_16] [PMID: 28469304]
[http://dx.doi.org/10.4103/iju.IJU_285_16] [PMID: 28469304]
[25]
de Cueto M, López L, Hernández JR, Morillo C, Pascual A. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Comparison of susceptibility testing procedures. Antimicrob Agents Chemother 2006; 50(1): 368-70.
[http://dx.doi.org/10.1128/AAC.50.1.368-370.2006] [PMID: 16377714]
[http://dx.doi.org/10.1128/AAC.50.1.368-370.2006] [PMID: 16377714]
[26]
Collins AM, Craig G, Zaiman E, Roy TE. A comparison between disk-plate and tube-dilution methods for antibiotic sensitivity testing of bacteria. Can. J. Public Health/Rev. Can Sante’e Publique 1954; 45: 430-9.
[PMID: 13209413]
[PMID: 13209413]
[27]
Baker CN, Stocker SA, Culver DH. Thorns berry, C. Comparison of the E Test to agar dilution, broth micro dilution, and agar di_usion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol 1991; 29(3): 533-8.
[http://dx.doi.org/10.1128/jcm.29.3.533-538.1991] [PMID: 2037671]
[http://dx.doi.org/10.1128/jcm.29.3.533-538.1991] [PMID: 2037671]
[28]
Sabharwal ER, Sharma R. Fosfomycin: An alternative therapy for the treatment of UTI amidst escalating antimicrobial resistance. J Clin Diagn Res 2015; 9(12): DC06-9.
[http://dx.doi.org/10.7860/JCDR/2015/15227.6951] [PMID: 26816887]
[http://dx.doi.org/10.7860/JCDR/2015/15227.6951] [PMID: 26816887]
[29]
Tabasi M, Karam MR, Habibi M, Mostafavi E, Bouzari S. Genotypic characterization of virulence factors in Escherichia coli isolated from patients with acute cystitis, pyelonephritis and asymptomatic bacteriuria. J Clin Diagn Res 2016; 10(12): DC01-7.
[http://dx.doi.org/10.7860/JCDR/2016/21379.9009] [PMID: 28208853]
[http://dx.doi.org/10.7860/JCDR/2016/21379.9009] [PMID: 28208853]
[30]
Demir T, Buyukguclu T. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis 2013; 17(11): e966-70.
[http://dx.doi.org/10.1016/j.ijid.2013.04.005] [PMID: 23742831]
[http://dx.doi.org/10.1016/j.ijid.2013.04.005] [PMID: 23742831]
[31]
Verdakas KZ. Lega kis NJ, Triarides N, Falagas ME. Susceptibility of contemporary isolates to fosfomycin: A clinical patterns of Pseudomonas aeruginosa. Rev Esp Quimioter 2016; 47(4): 269-85.
[32]
Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev 2016; 29(2): 321-47.
[http://dx.doi.org/10.1128/CMR.00068-15] [PMID: 26960938]
[http://dx.doi.org/10.1128/CMR.00068-15] [PMID: 26960938]
[33]
PerdigaoNeto LV Oliveira MS, Rizek CF, Carrilho CM, Costa SF, Levin AS. Susceptibility of multiresistant gramnegative bacteria to fosfomycin and performance of different susceptibility testing methods. Antimicrob Agents Chemother 2014; 58(3): 17637.
[34]
Rossignol L, Vaux S, Maugat S, et al. Incidence of urinary tract infections and antibiotic resistance in the outpatient setting: A cross-sectional study. Infection 2017; 45(1): 33-40.
[http://dx.doi.org/10.1007/s15010-016-0910-2] [PMID: 27234045]
[http://dx.doi.org/10.1007/s15010-016-0910-2] [PMID: 27234045]
[35]
Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013; 56(5): 641-8.
[http://dx.doi.org/10.1093/cid/cis942] [PMID: 23150211]
[http://dx.doi.org/10.1093/cid/cis942] [PMID: 23150211]
[36]
Zavala-Cerna MG, Macriz-Romero N, Santoscoy-Gutierrez JF, et al. High microbiological spectrum resistance rates in urine isolates from Jalisco, Mexico. A retrospective study and literature review. Int Arch Med 2015; 8(148): 1755-7682.
[http://dx.doi.org/10.3823/1747]
[http://dx.doi.org/10.3823/1747]
[37]
Zhanel GG, Walkty AJ, Karlowsky JA. Fosfomycin: A first-line oral therapy for acute uncomplicated cystitis. Can J Infect Dis Med Microbiol 2016; 20162082693
[http://dx.doi.org/10.1155/2016/2082693] [PMID: 27366158]
[http://dx.doi.org/10.1155/2016/2082693] [PMID: 27366158]
Article Metrics
17
1